Loading…
Employees: 2,945
Size Shanghai Runda Medical Technology (603108.SS) is a China Health Care company (Medical Specialties) with a market value of $909M, the 2497th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.02 on 6 Nov 2026.
Performance Over six months the shares fell 25.4%, against -13.3% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 11.9% over the last twelve months (peer median +11.1%); the operating margin is -2.3% (peer median 11.2%).
Valuation It trades at 25.1× forward earnings against a peer median of 21.4× (7th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥6.52B | CN¥6.98B | CN¥8.28B | CN¥9.11B | CN¥10.5B |
| Revenue growth | — | -16% | -9% | -13% | — |
| Gross profit | CN¥1.71B | CN¥1.39B | CN¥1.98B | CN¥2.30B | CN¥2.82B |
| EBITDA | n/a | CN¥371M | CN¥968M | CN¥1.11B | CN¥1.40B |
| Net income | -CN¥559M | -CN¥548M | CN¥55.3M | CN¥273M | CN¥418M |
| Free cash flow | CN¥724M | CN¥442M | CN¥444M | CN¥482M | -CN¥663M |
| Capital expenditure | CN¥237M | CN¥250M | CN¥229M | CN¥320M | CN¥272M |
| Total debt | CN¥5.81B | CN¥6.96B | CN¥7.09B | CN¥6.91B | CN¥7.04B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603108.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.7% | -6.2% | 6th highest of 21 |
| 6-month return | -25.4% | -13.3% | 4th lowest of 21 |
| Distance from 52-week high | -51.8% | -36.2% | 5th lowest of 21 |
| Revenue growth (TTM) | -11.9% | +11.1% | 2nd lowest of 21 |
| Operating margin | -2.3% | 11.2% | 3rd lowest of 21 |
| Forward P/E | 25.1× | 21.4× | 7th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 22.2% | 3.1% | 3rd most demanding of 16 |
| Growth delivered (Del g) | -0.2% | +11.7% | 3rd lowest of 16 |
| Hurdle (Req g minus delivered) | +22.4 pp | -5.1 pp | 2nd most demanding of 16 |
| ROIC minus cost of capital | -4.0 pp | +2.6 pp | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |